Deficiencies in DNA mismatch repair (MMR) result in replication errors within key tumor suppressor genes or oncogenes, and cause hereditary nonpolyposis colorectal cancer (HNPCC). Hematological malignancy with microsatellite instability is also associated with defective MMR, but little is known about the target genes for MMR. Here we identified Ikaros, a master transcription factor of lymphoid lineage commitment and differentiation, as a mutational target in spontaneous and radiation-induced T-cell lymphomas in Mlh1-deficient mice. Three quarters of lymphomas lacked Ikaros protein expression, which resulted from a frameshift mutation that created a stop codon. Mononucleotide repeat sequences at 1029-1034(C)6 and 1567-1572(G)6 in Ikaros were mutational hot spots with a one-base deletion occurring with a frequency of 45 and 50%, respectively. Point mutations and splicing alterations were also observed. In total, 85% of the lymphomas showed aberrations in Ikaros. The characteristic of Mlh1-deficient lymphomas is harboring of multiple mutations simultaneously in the same tumor, displaying a combination of two frameshift mutations at different repeats, frameshift and point mutations, and/or deletion mutations. This is the first report of Ikaros mutations coupled with Mlh1 deficiency in lymphomagenesis. Oncogene (2007) 26, 2945-2949. doi:10.1038/sj.onc.1210100; published online 6 November 2006
Keywords: T-cell lymphoma; DNA mismatch repair; coding microsatellites; microsatellite instability; mutational target gene Deficiencies in DNA mismatch repair (MMR) result in replication errors that cause frameshift mutations and/ or point mutations within key tumor suppressor genes or oncogenes . Heterozygous germline mutations in MMR genes such as MSH2, MLH1 and PMS2 are the cause of hereditary nonpolyposis colorectal cancer (HNPCC) (Fishel et al., 1993; Leach et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994) . In these cancers, frameshift mutations in 8-10 mononucleotide repeat sequences in TGFbRII, BAX, hMSH3, hMSH6 and IGFIIR genes have been frequently reported. Homozygous germline mutations of MMR genes are also manifested by an early onset of childhood T-or B-cell leukemias (Wang et al., 1997; Ricciardone et al., 1999; De Vos et al., 2006) . Analogous to the human phenotype, MMRdeficient mice develop aggressive lymphomas, which are predominantly of T-cell origin (Reitmair et al., 1995) . These MMR-deficient lymphomas show a significant increase in both point mutations and microsatellite instability (MSI) in the mononucleotide repeat sequences (Yao et al., 1999; Baross-Francis et al., 2001; Gu et al., 2002; Kabbarah et al., 2003) . However, the mutational target gene in these leukemias has not been identified (Campbell et al., 2000) . Only insertional mutation of TgfbrII has been reported in Msh2-deficient murine lymphomas (Lowsky et al., 2000) .
Ikaros is a transcription factor that plays a key role in lineage commitment and differentiation in lymphoid cells (Georgopoulos et al., 1992) . Dominant-negative Ikaros isoforms are reportedly expressed in human acute T-and B-lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) (Nakayama et al., 1999; Sun et al., 1999a, b) . Others and we have reported not only the expression of dominant-negative isoforms but also null expression and point mutations in radiationand chemical-induced mouse T-cell lymphomas (Okano et al., 1999; Shimada et al., 2000; Kakinuma et al., 2002 Kakinuma et al., , 2005 Karlsson et al., 2002) . Furthermore, homozygous null mice and mice heterozygous for the Ikaros dominant-negative isoforms or Ikaros Plstic mutants exhibit T-cell hyperproliferation and ultimately die of T-cell lymphomas (Winandy et al., 1995; Wang et al., 1996; Papathanasiou et al., 2003) . Thus, the Ikaros aberration correlates strongly with T-cell lymphomagenesis. As Ikaros gene has mononucleotide repeat sequences of four (C)6 and one (G)6 repeats, we were compelled to examine Ikaros mutations in Mlh1-deficient lymphomas.
Here we showed that an extremely high proportion of Mlh1-deficient lymphomas (75%) lacks expression of Ikaros protein. This was ascribed to frameshift mutations in the gene Ikaros, most of which were one-base deletions in a mononucleotide repeat sequence that created a stop codon. Dinucleotide deletion and point mutations were also found. Thus, Ikaros is a likely target for MMR deficiency-mediated mutagenesis during the development of T-cell lymphoma.
In the present study, we first evaluated the expression of TgfbrII protein in 20 Mlh1-deficient lymphomas, because insertional mutations in TgfbrII have been reported in Msh2-deficient murine lymphomas (Lowsky et al., 2000) . All lymphomas produced the TgfbrII protein at the same level as that in normal thymus (Supplement 1), and gene sequencing found no frameshift mutation. Thus, in contrast with Msh2-deficient lymphomas, TgfbrII is not a mutational target in Mlh1-deficient lymphomas.
Next, we analysed the expression of Ikaros protein in Mlh1-deficient lymphomas. Surprisingly, 15 out of 20 lymphomas (75%) lacked Ikaros protein (lanes 2, 3, 4, 6, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 and 19 shown in Figure 1 Expression of Ikaros in Mlh1-deficient lymphomas. Mlh1-knockout mice were generated and genotyped by PCR as described previously (Baker et al., 1996; Tokairin et al., 2006) . T-cell lymphomas of Mlh1-knockout mice developed either spontaneously or upon exposure to whole-body X-irradiation at 2 Gy (Tokairin et al., 2006) . Expression of Ikaros and b-actin proteins was analysed by Western blotting, and that of Ikaros mRNA was analysed by RT-PCR, using primers Ik2F and Ik7R, respectively; Gapdh mRNA was analysed as a control using sense and antisense primers (Kakinuma et al., 2002) . Western blot analysis of Ikaros expression (upper panel) and RT-PCR analysis of Ikaros expression (lower panel) in normal thymocytes of Mlh1 þ / þ mice (lane 1) and in Mlh1-deficient T-cell lymphomas (lanes 2-21) were shown. Lanes 1-21 are in the same order as the samples in Table 1 (samples 1-21). Normal thymocytes and lymphoma express two forms of Ikaros (Ik-1 and Ik-2), the latter of which lacks exon 2 as a result of alternative splicing. Figure 2 Mutation of Ikaros in Mlh1-deficient lymphomas. PCR was performed using AccuPrime Taq DNA Polymerase High Fidelity (Invitrogen, San Diego, CA, USA). Mutation analysis of Ikaros was performed in at least three steps for both Mlh1-deficient lymphomas and Mlh1-proficient normal thymocytes. First, the entire Ikaros cDNA (exons 1-7) was amplified in three pieces using three primer sets, Ik1F and Ik4R, Ik3F(2) and Ik6R, Ik6F(2) and Ik7R(4). The products were directly sequenced by primers Ik1F, Ik4R, Ik3F(2), Ik6R, Ik6F(2) and Ik7R(4). Second, the PCR products predicted to contain point or frameshift mutations were subjected to TA cloning, and at least 10 clones per sample were sequenced (Kakinuma et al., 2002) . Third, all the lymphomas harboring more than two mutations were reanalysed to elucidate whether each mutation existed on the same or independent mRNA fragments. The entire Ikaros gene was amplified using primers Ik1F and Ik7R(4) and sequenced following TA cloning, as has been reported previously (Kakinuma et al., 2002) . The lower panels depict the sequence regions of frameshift mutations, and the upper panels represent the respective regions for the wild-type loci. Example of sequence profiles in the region containing the mononucleotide repeats 89-94(C)6, sample 8; 117-120(G)4, sample 3; 1029-1034(C)6, sample 9; 1100-1105(C)6, sample 7; 1567-1572(G)6, sample 9; and dinucleotide repeat 1516-1521(TG)3, sample 16. 
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Ikaros in Mlh1-deficient mice S Kakinuma et al Figure 1 top panel) , of which two (lanes 8 and 10) had marginally detectable Ikaros. Two lymphomas expressed a reduced amount of protein (lanes 7 and 11), and three had the same level of Ikaros protein as the control (lanes 5, 20 and 21). Reverse trancriptase-polymerase chain reaction (RT-PCR) analysis, however, revealed that all lymphomas expressed Ikaros mRNA (Figure 1) . Thus, a lack of Ikaros protein was not due to transcriptional silencing (Kakinuma et al., 2002) .
We then examined the mutations in Ikaros gene. We found that 17 of 20 lymphomas (85%) harbored frameshift mutations that created stop codons (Figure 2 , Table 1 ). Six lymphomas (samples 2, 4, 14, 7, 8 and 11) had one-base deletions; the former three each, had a homozygous mutation in either 1029-1034(C)6 or 1567-1572(G)6 and did not express any Ikaros protein, and the latter three had heterozygous mutations and expressed a reduced amount of Ikaros protein. Nine lymphomas harbored two different frameshift mutations simultaneously: six lymphomas (samples 3, 12, 13, 15, 16 and 17) harbored mutations in two of the following five mononucleotide repeat sequences: 89-94(C)6, 117-120(G)4, 1029-1034(C)6, 1100-1105(C)6 or 1567-1572(G)6, and three lymphomas (samples 6, 9 and 19) harbored one-base deletions in both 1029-1034(C)6 and 1567-1572(G)6 in the same clone. These two mononucleotide repeats were mutational hot spots in Ikaros, with the incidence of mutation at 45 and 50%, respectively. Notably, the mononucleotide repeats identified as mutational targets in Ikaros were 4-6 nucleotides long, which is significantly shorter than the repeats of more than eight nucleotides in MMR target genes found in tumors with high MSI (Duval and Hamelin, 2002; Woerner et al., 2005) . These frameshift mutations result in an aberrant amino-acid sequence and a premature stop codon, and the truncated Ikaros proteins were apparently degraded in the lymphomas. In the mice lacking exon 7 of Ikaros gene, where dimerization domain is encoded, the resultant truncated Ikaros protein is shown to be unstable and rapidly degraded in the lymphoma cells (Wang et al., 1996) .
The remaining three lymphomas (samples 9, 10 and 18) had more complex mutations. Sample 18 harbored an independent one-base deletion and point mutation, both of which resulted in stop codons. Samples 9 and 10 harbored not only one-base deletions in mononucleotide repeats but also point mutations and a 30-bp deletion at the 3 0 -end of exon 6; this 30-bp deletion has been reported in human and mouse leukemia (Sun et al., 1999b; Kakinuma et al., 2002) . In addition to the mutations mentioned above, sample 16 also had a dinucleotide deletion in a short repeat of 1516-1521(TG)3. These complex mutations were found in only radiation-induced lymphomas, but not spontaneous one, suggesting radiation-induced genomic instability (Nakanishi et al., 2001; Shimada et al., 2003) . Frameshift mutations and multiple mutations of Ikaros within the same lymphoma have only rarely been reported in radiation-or chemical-induced lymphomas developed in wild-type inbred mice (Okano et al., 1999; Kakinuma et al., 2002; Karlsson et al., 2002) . Thus, these mutations are closely linked to Mlh1 deficiency. We previously reported that Ikaros mutation spectrum is influenced by carcinogen, which causes different types of DNA damage (Shimada et al., 2000; Kakinuma et al., 2002 Kakinuma et al., , 2005 . The present result suggests that a balance (or distortion) of DNA repair systems is also an important determinant for the spectrum.
In summary, this study demonstrates that Ikaros is a mutational target gene that contributes to leukemogenesis in the absence of Mlh1 function. The majority of mutations identified were frameshifts that resulted from one-base deletions in six mononucleotide repeat sequences, thereby disrupting Ikaros protein expression. These findings strongly predict the involvement of mutation of IKAROS in MLH1-deficient human leukemia.
